Thoracic radiotherapy synergizes with first‐line EGFR ‐ TKIs in advanced EGFR ‐mutant NSCLC : A dual‐center real‐world study

Documenti analoghi

• Sacituzumab tirumotecan improved survival for patients with EGFR TKI–resistant, EGFR‐mutant advanced NSCLC
  di: Leah Lawrence
  Pubblicazione: (2026)
• More treatment options emerge for EGFR ‐mutant NSCLC
  di: Leah Lawrence
  Pubblicazione: (2026)
• Clinical Outcomes of Later‐Generation EGFR ‐ TKIs for Uncommon EGFR Mutations in NSCLC : A Multicenter Real‐World Study
  di: Lisa Shigematsu, et al.
  Pubblicazione: (2025)
• Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR‐TKIs
  di: Zhenbang Gu, et al.
  Pubblicazione: (2024)
• Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study
  di: Shuai Liang, et al.
  Pubblicazione: (2024)